Allarity Therapeutics (NASDAQ:ALLR) Given New $10.25 Price Target at Ascendiant Capital Markets

Allarity Therapeutics (NASDAQ:ALLR) had its price target hoisted by analysts at Ascendiant Capital Markets from $9.75 to $10.25 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Other analysts also recently issued research reports about the company. Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research note on Saturday, May 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Stock Performance

Shares of Allarity Therapeutics stock opened at $1.61 on Monday. The company has a market capitalization of $25.62 million, a PE ratio of -2.24 and a beta of 0.52. Allarity Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.35. The stock’s fifty day simple moving average is $1.40 and its 200 day simple moving average is $1.20.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.05. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. Analysts predict that Allarity Therapeutics will post -0.96 EPS for the current fiscal year.

Institutional Trading of Allarity Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after acquiring an additional 16,729 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Allarity Therapeutics in the 2nd quarter valued at about $27,000. XTX Topco Ltd bought a new position in shares of Allarity Therapeutics in the 4th quarter valued at about $36,000. Citadel Advisors LLC bought a new position in shares of Allarity Therapeutics in the 3rd quarter valued at about $149,000. Finally, Capital Advisors Inc. OK bought a new position in shares of Allarity Therapeutics in the 4th quarter valued at about $108,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.